Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis

New drug approvals for 2022: Synthesis and clinical applications

“…In short, something innovative such as the first sterol 14α-demethylase (CYP51) inhibitor for the treatment of recurrent vulvovaginal candidiasis (RVVC), the first granulocyte-colony stimulating factors (G-CSFs) for the treatment of febrile neutropenia (FN), the first semiannual capsid inhibitor for the treatment of human immunodeficiency virus (HIV), the first dual orexin receptor antagonist for the treatment of insomnia, the first peptide exchange technique (PTX)-stabilized neuro-regulator for the treatment of glabellar lines, the first nonsteroidal topical drug for the treatment of plaque psoriasis, the first therapy for the treatment of generalized pustular psoriasis (GPP), as well as the first tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, and so on, were realized in 2022 to provide new direction for the development of more potent drug molecules. [7][8][9][10][11][12][13][14] In addition, 22 new drugs were defined as the first-in-class to bring innovative therapy, and 10 new drugs were approved as the breakthrough designation to provide the improved clinical efficacy. Oncology remains the dominant therapeutic area with 11 new drugs and biologics approved for marketing.…”